A whole new era of communication in GLP-1 is here!
Now you’ve got the sharpest minds in GLP-1 research right in your pocket. What’s best?
You can listen to them while driving to the hospital, walking between labs, traveling, or just running errands. It’s never been this good or this simple.
Welcome to The GLP-1 Podcast Show, a monthly podcast where you’ll hear cutting-edge perspectives and what’s working in the world of GLP-1. Our aspiration is to be the first place you are going to go to find out what's happening, the latest breakthroughs, clinical updates, and innovations in GLP-1 care and research.
Dr. Ian Justl Ellis: Personalizing GLP-1 Dosing | Ep. 17
Host [Host Name] interviews Dr. Ian Justl Ellis, a board-certified physician, about personalizing GLP-1 dosing for optimal patient outcomes.
19 Oct 2026TRANSCRIPT
Dr. Anders Fink-Jensen: GLP-1 Therapy for Alcohol Use Disorder | Ep. 16
Host interviews Dr. Anders Fink-Jensen, Professor of Psychiatry, exploring GLP-1 therapy's emerging role in treating alcohol use disorder and its impact on craving.
5 Oct 2026TRANSCRIPT
Dr. Michelle Gordon: GLP-1 Care for Women in Midlife | Ep. 15
Host interviews Dr. Michelle Gordon, a physician board-certified in obesity medicine, about GLP-1 therapy's role in managing midlife women's health and complex chronic disease.
21 Sept 2026TRANSCRIPT
Dr. Jon Campbell: Understanding GIP and Glucagon | Ep. 14
Host interviews Dr. Jon Campbell, Associate Professor of Medicine at Duke University, exploring GIP and glucagon's evolving roles in metabolic disease treatment.
7 Sept 2026TRANSCRIPT
Dr. Ashley Koff: Weight Health in the GLP-1 Era | Ep. 13
Host interviews registered dietitian Dr. Ashley Koff about optimizing weight health and metabolic function within the GLP-1 era, emphasizing personalized nutrition and body composition.
24 Aug 2026TRANSCRIPT
Dr. Timothy Garvey: Adiposity-Based Chronic Disease Explained | Ep. 12
Dr. W. Timothy Garvey, Endowed Professor of Medicine at the University of Alabama at Birmingham, explains complication-centric care for Adiposity-Based Chronic Disease in this interview.
3 Aug 2026TRANSCRIPT
Dr. Christopher Kramer: Tirzepatide And Cardiovascular Health | Ep. 11
Host interviews Dr. Christopher Kramer, Chief of Cardiovascular Division at UVA Health, about how GLP-1 and GIP therapies significantly improve cardiovascular health and reduce heart failure events.
6 Jul 2026TRANSCRIPT
Dr. Richard DiMarchi: The Evolution of GLP-1 Science | Ep. 10
Host interviews Dr. Richard DiMarchi, Distinguished Professor at Indiana University, exploring the evolution of GLP-1 science and future obesity treatments.
1 Jun 2026
Dr. Sandra Christensen: Preserving Muscle During GLP-1 Treatment | Ep. 09
In this episode of The GLP-1 Podcast Show, I speak with Dr. Sandra Christensen, obesity medicine specialist and founder of Integrative Medical Weight Management. We examine how GLP-1 therapies impact body composition beyond total weight loss. Dr. Christensen explores fat-free mass reduction, muscle and bone considerations, and clinical risks. She also addresses nutrition strategies, resistance training, and the importance of structured monitoring and personalized care. Listen now on all major platforms!
"When evaluating weight reduction outcomes, it is essential to distinguish between fat mass and fat-free mass, because each component has different physiological roles and clinical implications."
Meet the guest: Dr. Sandra Christensen https://www.linkedin.com/in/sandra-christensen/ is an obesity medicine specialist and founder of Integrative Medical Weight Management in Seattle. She holds advanced certification in obesity medicine and serves as a trustee for the Obesity Medicine Association and president of the Washington Obesity Society. Her work focuses on clinical strategies, patient care, and education in obesity treatment. Learn more from Dr. Sandra Christensen on The GLP-1 Podcast Show, available on all major platforms.
What you will learn:
(00:00) Highlight
(00:43) Introduction
(02:10) Body composition
(03:45) Fat-free mass
(07:22) Protein strategies
(11:44) Resistance training
(14:27) Monitoring tools
(25:23) Final Questions
𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.
Website: https://www.wisenetix.com/glp1
Instagram: https://www.instagram.com/theglp1podcast/
LinkedIn: https://www.linkedin.com/showcase/the-glp-1-podcast-show/
4 May 2026
Dr. Jason Itri: GLP-1 Microdosing Strategy | Ep. 08
In this episode of The GLP-1 Podcast Show, I speak with Dr. Jason Itri, Founder of Longevity Health Clinic, about how GLP-1 therapies extend beyond weight loss into cardiometabolic optimization. We examine microdosing strategies, insulin resistance, inflammation pathways, and sustainable habit formation through precision prescribing. Dr. Itri highlights practical clinical applications for long-term metabolic health. Listen now on all major platforms!
"Lower dose GLP-1 strategies can improve control over dietary habits by reducing impulsive food decisions and supporting consistent behavioral patterns over extended periods."
Meet the guest: Dr. Jason Itri https://www.linkedin.com/in/jason-itri-20962326/ is a physician and the founder of Longevity Health Clinic in Virginia, specializing in cardiometabolic health, hormone optimization, and GLP-1 therapies. His work integrates biomarker testing with root-cause physiology to improve metabolic outcomes and reduce long-term disease risk. His clinical focus aligns with advancing precision approaches in obesity medicine and metabolic care.
What you will learn:
(00:00) Highlight
(00:48) Introduction
(04:49) Microdosing strategy
(07:07) Habit control
(14:51) Risk markers
(16:51) Insulin resistance
(28:50) Muscle loss
(32:00) Final Questions
𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.
Website: https://www.wisenetix.com/glp1
Instagram: https://www.instagram.com/theglp1podcast/
LinkedIn: https://www.linkedin.com/showcase/the-glp-1-podcast-show/
6 Apr 2026
Dr. Catherine Toomer: GLP-1 Dosing Strategy | Ep. 07
In this episode of The GLP-1 Podcast Show, I speak with Dr. Catherine Toomer, founder of Total Weight Care Institute and a family medicine physician specializing in metabolic disease. The discussion examines long-term clinical experience using GLP-1 therapies, including dosing strategies, metabolic regulation, and patient-centered obesity care. She also explores insulin resistance, brain signaling, and emerging therapeutic applications. Listen now on all major platforms!
“Appetite regulation is strongly influenced by brain signaling pathways, and correcting metabolic signaling often changes hunger perception and eating behavior without relying on willpower alone.”
Meet the guest: Dr. Catherine Toomer https://www.linkedin.com/in/drtoomer/ is a family medicine physician and founder of Total Weight Care Institute, with more than fifteen years of clinical experience using GLP-1 therapies to address metabolic disease and obesity. Her work focuses on correcting metabolic dysregulation through evidence-based medical strategies and personalized care.
What you will learn:
(00:00) Highlight
(00:31) Introduction
(01:52) Metabolic disease drivers
(05:33) Personalized dosing strategy
(07:17) Managing side effects
(19:44) Brain appetite signaling
(22:40) Future applications
(24:50) Final Questions
𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.
Website: https://www.wisenetix.com/glp1
Instagram: https://www.instagram.com/theglp1podcast/
LinkedIn: https://www.linkedin.com/showcase/the-glp-1-podcast-show/
2 Mar 2026
Dr. Caroline Apovian: GLP-1 Game Changers | Ep. 06
In this episode of The GLP-1 Podcast Show, I speak with Dr. Caroline Apovian, Professor of Medicine at Harvard Medical School and Co Director of the Center for Weight Management and Wellness at Brigham and Women’s Hospital, about the evolution of obesity treatment. We discuss why obesity is a chronic disease, how GLP-1 based therapies have changed clinical outcomes, and how they compare with lifestyle intervention and metabolic surgery. Dr. Apovian also addresses stigma, access barriers, and the risks of cosmetic use. Listen now on all major platforms!
"Stigma surrounding obesity has forced clinicians to repeatedly prove that treating obesity also prevents cardiovascular disease and diabetes."
Meet the guest: Dr. Caroline Apovian https://www.linkedin.com/in/drapovian/ is Professor of Medicine at Harvard Medical School and Co Director of the Center for Weight Management and Wellness at Brigham and Women’s Hospital. A founding leader in obesity medicine, her research focuses on adipose tissue inflammation, cardiovascular risk, metabolic surgery, and pharmacotherapy for obesity.
What you will learn:
(00:00) Highlight
(01:02) Introduction
(04:20) GLP-1 overview
(07:34) Obesity disease model
(13:14) Treatment comparisons
(19:38) Cardiovascular outcomes
(25:23) Cosmetic use debate
(33:01) Final Questions
𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.
Website: https://www.wisenetix.com/glp1
Instagram: https://www.instagram.com/theglp1podcast/
LinkedIn: https://www.linkedin.com/showcase/the-glp-1-podcast-show/
2 Feb 2026
Melissa Mitri: Nutrition & GLP-1’s | Ep. 05
In this episode of The GLP-1 Podcast Show, I speak with Melissa Mitri, Registered Dietitian and weight loss expert at Melissa Mitri Nutrition, about real-world nutrition strategies for patients using GLP-1 therapies. She focuses on nutrient density, meal structure, side effect management, muscle preservation, and long-term habit building. Melissa shares clinical insights from nearly two decades of practice working directly with patients. Melissa highlights how nutrition and lifestyle optimize outcomes alongside GLP-1 medications. Listen now on all major platforms!
“GLP-1 therapies shift nutrition counseling away from calorie obsession toward nutrient density, because patients eat smaller portions and every bite must support metabolic health.”
Meet the guest: Melissa Mitri, MS, RD, is a Registered Dietitian, weight loss expert, and founder of Melissa Mitri Nutrition. She specializes in sustainable weight management, including nutrition support for patients using GLP-1 therapies. With nearly 20 years of clinical experience, her work focuses on nutrient density, habit formation, and evidence based care.
Connect with our guest on Social Media:
LinkedIn: https - www.linkedin.com/in/melissa-mitri-ms-rd-9539789/
Instagram - https://www.instagram.com/theweightloss.dietitian?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==
GLP-1 Cheat Sheet for Clinicians - https://buy.stripe.com/8wMfZa6lRaMK9jieUU
What you will learn:
(00:00) Highlight
(00:45) Introduction
(02:27) Nutrition approach
(04:59) Meal timing
(07:23) Side effects
(12:14) Muscle preservation
(17:35) Long-term habits
(29:49) Final Questions
𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.
Website: https://www.wisenetix.com/glp1
Instagram: https://www.instagram.com/theglp1podcast/
LinkedIn: https://www.linkedin.com/showcase/the-glp-1-podcast-show/
5 Jan 2026
Dr. Ken Fujioka: Next GLP-1 Era | Ep. 04
In this episode of The GLP-1 Podcast Show, I speak with Dr. Ken Fujioka, Clinical Professor of Medicine and Director of the Nutrition and Metabolic Research Center at Scripps Clinic, about the clinical evolution of GLP-1-based therapies. He covers next-generation dual and triple agonists, dose titration, nausea management, and long-term weight maintenance. Dr. Fujioka also examines oral alternatives, safety concerns, and real-world prescribing considerations. Listen now on all major podcast platforms!
"Combining multiple satiety hormones allows greater weight reduction by targeting complementary brain and gastrointestinal pathways involved in appetite regulation."
Meet the guest: Dr. Ken Fujioka is a Clinical Professor of Medicine and Director of the Nutrition and Metabolic Research Center at Scripps Clinic, specializing in obesity, diabetes, and metabolic disease management. His work focuses on clinical trials, patient-centered weight treatment, and GLP-1-based therapies.
What you will learn:
(00:00) Highlight
(00:57) Introduction
(02:59) New GLP-1 agents
(05:12) Dose titration
(08:14) Glucagon role
(10:29) Clinical precautions
(12:53) Oral alternatives
(22:42) Final Questions
𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.
Website: https://www.wisenetix.com/glp1
Instagram: https://www.instagram.com/theglp1podcast/
LinkedIn: https://www.linkedin.com/showcase/the-glp-1-podcast-show/
1 Dec 2025
Dr. Jens Juul Holst: GLP-1 in Modern Medicine | Ep. 03
In this episode of The GLP-1 Podcast Show, I speak with Dr. Jens Juul Holst, Professor of Medical Physiology at the University of Copenhagen and Senior Group Leader at the Novo Nordisk Foundation Center for Basic Metabolic Research. We explore the discovery of GLP-1, its evolution into today’s leading therapies for diabetes and obesity, and the molecular and clinical mechanisms that drive their success. Listen now on all major platforms.
“The incretin hormones GLP-1 and GIP amplify insulin secretion after meals, ensuring glucose tolerance and maintaining energy balance across multiple tissues.”
Meet the guest: Dr. Jens Juul Holst is Professor of Medical Physiology at the University of Copenhagen and Senior Group Leader at the Novo Nordisk Foundation Center for Basic Metabolic Research. His research focuses on metabolic hormones, appetite regulation, and the pathophysiology of obesity and type 2 diabetes. Known for co-discovering GLP-1, his work has shaped modern metabolic therapy.
What you will learn:
(00:00) Highlight
(00:35) Introduction
(01:44) GLP-1 mechanism
(04:37) Discovery process
(07:12) Therapeutic development
(10:56) Cardiovascular effects
(14:45) Broader metabolic impact
(20:04) Final Questions
𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.
Website: https://www.wisenetix.com/glp1
Instagram: https://www.instagram.com/theglp1podcast/
LinkedIn: https://www.linkedin.com/showcase/the-glp-1-podcast-show/
3 Nov 2025
Dr. Michael Nauck: GLP-1 Origins | Ep. 02
In this episode of The GLP-1 Podcast Show, I speak with Dr. Michael Nauck, Head of Clinical Research at the Diabetes Division of St. Josef-Hospital, Ruhr-University Bochum, Germany. We explore the early discoveries behind incretin hormones, the development of GLP-1–based therapies, and their expanding role in diabetes, obesity, and cardiovascular care. Dr. Nauck also discusses the next generation of dual and triple agonists shaping obesity medicine. Listen now on all major platforms.
“For the first time, weight loss medications, like GLP-1, achieved meaningful reductions without serious safety concerns.”
Meet the guest: Dr. Michael Nauck is Head of Clinical Research at the Diabetes Division, St. Josef-Hospital, Ruhr-University Bochum, Germany. His pioneering work on incretin hormones established the scientific foundation for GLP-1–based therapies in type 2 diabetes. With a research focus on metabolic regulation and cardiovascular outcomes, Dr. Nauck continues to advance innovation in endocrinology and obesity care.
What you will learn:
(00:00) Highlight
(00:46) Introduction
(01:55) Incretin effect explained
(06:15) Early GLP-1 discoveries
(08:16) DPP-4 inhibitors’ role
(11:49) Beyond glucose control
(16:21) Mechanisms of GLP-1
(22:28) Final Questions
𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.
Website: https://www.wisenetix.com/glp1
Instagram: https://www.instagram.com/theglp1podcast/
LinkedIn: https://www.linkedin.com/showcase/the-glp-1-podcast-show/
29 Sept 2025
Dr. Michael Schwartz: GLP-1 and Brain Pathways | Ep. 01
The GLP-1 Podcast Show is a new podcast created to spotlight the science, perspectives, and leaders shaping the future of obesity treatment and metabolic medicine. In this first episode, we welcome Dr. Michael Schwartz, Robert H. Williams Endowed Chair and Professor of Medicine at the University of Washington, who speaks with Areesha Moiz about how GLP-1 receptor agonists reshape obesity treatment. The discussion covers adaptive responses to weight loss, brain regulation of appetite, mechanisms of long-acting drugs, and the challenges of sustaining results after treatment withdrawal. It also highlights emerging therapeutic strategies to prolong weight loss. Listen now on all major platforms!
"GLP-1 receptor agonists are unique because they continuously and maximally activate their target, creating effects that natural peptides could never achieve."
Meet the guest: Dr. Michael Schwartz received his MD from Rush Medical College and trained in endocrinology and metabolism at the University of Washington. He is internationally recognized for his research on brain mechanisms controlling body weight, glucose homeostasis, obesity, and diabetes. A recipient of numerous awards, Dr. Schwartz has published nearly 300 papers and directed major research institutes in Seattle.
What you will learn:
(00:00) Highlight
(01:15) Introduction
(03:26) GLP-1 drug design
(07:51) Appetite regulation
(10:23) Adaptive response
(14:39) Weight regain
(17:55) Maintenance strategies
(24:44) Final Questions
𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.
Website: The GLP-1 Podcast Show (https://www.wisenetix.com/glp1)
Instagram: The GLP-1 Podcast Show (https://www.instagram.com/theglp1podcast/)
LinkedIn: The GLP-1 Podcast Show (https://www.linkedin.com/showcase/the-glp-1-podcast-show/)
30 Jun 2025
Welcome to The GLP-1 Podcast Show!
A whole new era of communication in GLP-1 is here!
Now you’ve got the sharpest minds in GLP-1 research right in your pocket. What’s best?
You can listen to them while driving to the hospital, walking between labs, traveling, or just running errands. Now it’s never been this good or this simple.
Welcome to The GLP-1 Podcast Show, a monthly podcast where you’ll hear cutting-edge perspectives and what’s working in the world of GLP-1.
Our aspiration is to be the first place you are going to go to find out what's happening, the latest breakthroughs, clinical updates, and innovations in GLP-1 care and research.
Inside a recent episode
Dr. Ian Justl Ellis: Personalizing GLP-1 Dosing | Ep. 17
Published 2 Nov 2026 · Transcript excerpt
[…] We'll tell you the right dose to take to have that every time and see what happens. And what happened is, just to put a pin in it, they still lost weight, faster than the trials in many cases, on much fewer medicine, and we didn't have attrition due to side effects because if they experienced side effects, What would we do? […]
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
